News Release

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

KemPharm to Present at Two Healthcare Investor Conferences During September 2018

September 5, 2018 at 7:30 AM EDT

CORALVILLE, Iowa, Sept. 05, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis C. Mickle, Ph.D., will present at the Janney Montgomery Scott Healthcare Conference being held September 17-18, 2018.  He will also attend one-on-one investor meetings at the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease, to be held September 26-27, 2018.  Both conferences are in New York City.

Details of KemPharm's presentation and one-on-one investor meetings are as follows:

Conference:     Janney Montgomery Scott Healthcare Conference 2018
Date:                Monday, September 17, 2018
Time:                9:55 am (ET)
Location:          Union League Club, 38 East 37th Street, New York, NY 10016

Conference:     Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease
Date:                Wednesday, September 26, 2018
Time:                8:00 am to 5:00 pm (ET)
Location:          The Langham, 400 Fifth Avenue, New York, NY 10018

The Janney Healthcare Conference presentation will be webcast and available on the Investor Relations section under “Events & Presentations” on the Company's website at http://investors.kempharm.com/.

About KemPharm
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) platform technology.  KemPharm utilizes its proprietary LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of ADHD, pain and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release/effect profiles for the treatment of ADHD.  In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product candidate of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.  For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.

Investor/Media Contacts:   
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664
jrando@tiberend.com
jdrumm@tiberend.com
 
 

KemPharm Logo

Source: KemPharm